Try our mobile app

Completion of the Acquisition of a Portfolio of Products in Latin America from Viatris

Published: 2023-11-01 11:00:35 ET
<<<  go to JSE:APN company page
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or the “Group”)

COMPLETION OF THE ACQUISITION OF A PORTFOLIO OF PRODUCTS IN LATIN AMERICA FROM VIATRIS

Shareholders are referred to the announcement of 1 August 2023 wherein it was confirmed that Aspen
Global Incorporated, incorporated in Mauritius, a wholly owned subsidiary of Aspen Holdings, had executed
an agreement pursuant to which it would acquire from Viatris Inc. the commercialisation rights and related
intellectual property for a portfolio of well-known branded products in Latin America (the “Transaction”).

Aspen is pleased to confirm that the Transaction closed on 1 November 2023.

The key products within the portfolio are sold under the brand names Lipitor, Viagra, Lyrica, Zoloft, Norvasc,
and Celebrex.


Durban
01 November 2023

Sponsor
Investec Bank Limited